ArticleImmunity2024
The CD8
Abstract read
In one paragraph
Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hyperbaric oxygen therapy modulates immune effector responses and reshapes peripheral immune tolerance: a narrative review.Frontiers in immunology · 2026Pooled it
- Lymphatic metastasis of lung adenocarcinoma characterized by network with correlations between microbiota and upregulated gene sets involved in tumor migration and development.Chinese medical journal · 2026Article
- CD8Nature reviews. Cardiology · 2026Review
- CD8 T Cell Sensing of Type I Interferon Impacts Anergy.European journal of immunology · 2026Article
- Article
- Stress-induced sympathetic hyperactivation drives hair follicle necrosis to trigger autoimmunity.Cell · 2026Article
- Epigenetic regulation of T cell exhaustion in cancer.Nature reviews. Cancer · 2026Review
- Bulk RNAseq Analysis of Cardiac Myosin-Specific CD4Biomedicines · 2025Article
- The diversity of CD8Nature reviews. Immunology · 2025Review
- A Dapl1Science advances · 2025Article
- PD-1 expressing islet-specific CD4Immunology and cell biology · 2025Article
- Advances in molecular pathology and therapy of non-small cell lung cancer.Signal transduction and targeted therapy · 2025Review
- Reduced Function of the Adaptor SH2B3 Promotes T1D via Altered Cytokine-Regulated, T-Cell-Intrinsic Immune Tolerance.Diabetes · 2025Article
- Phenotypic and spatial heterogeneity of CD8Molecular cancer · 2024Review
Corrections and comments
- Commented on byCD82024
Authors and funding
28 authors.
Willem Van Der BylThe Kirby Institute for Infection and Immunity, UNSW, Sydney, NSW, Australia; School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Simone NüssingCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Timothy J PetersGarvan Institute of Medical Research, Sydney, NSW, Australia; University of New South Wales Sydney, Sydney, NSW, Australia.
Antonio AhnCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Hanjie LiDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Guy LedergorDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Eyal DavidDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Andrew S KohDepartment of Pathology, University of Chicago, Chicago, IL, USA.
Mayura V WagleGarvan Institute of Medical Research, Sydney, NSW, Australia; John Curtin School of Medical Research, ANU, Canberra, ACT, Australia.
Christian Deo T DeguitCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Maria N de MenezesCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Avraham TraversCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Shienny SampurnoCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Kelly M RamsbottomCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Rui LiCenter for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA.
Axel KalliesThe Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia; Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia.
Paul A BeavisCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Ralf JungmannFaculty of Physics and Center for Nanoscience, Ludwig Maximilian University, Munich, Germany; Max Planck Institute of Biochemistry, Martinsried, Germany.
Maartje M C BastingsInstitute of Materials, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Interfaculty Bioengineering Institute, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Gabrielle T BelzThe Frazer Institute, The University of Queensland, Brisbane, QLD, Australia; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Shom GoelCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Joseph A TrapaniCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Gerald R CrabtreeCenter for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA; Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA.
Ido AmitDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Chris C GoodnowSchool of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia.
Fabio LucianiThe Kirby Institute for Infection and Immunity, UNSW, Sydney, NSW, Australia; School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia. Electronic address: luciani@unsw.edu.au.
Ian A ParishCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia; John Curtin School of Medical Research, ANU, Canberra, ACT, Australia. Electronic address: ian.parish@petermac.org.
Funding
ATP-Dependent Chromatin Remodeling in Human MalignancyR01CA163915 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree · 2012 to 2026
$5.4MHIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCLR01CA276167 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree, NATHANAEL Schiander GRAY · 2023 to 2026
$2.2MNCI NIH HHS R01 CA163915NCI NIH HHS R01 CA276167
Abstract
Peripheral CD8
Indexed as
CD8-Positive T-LymphocytesCell DifferentiationImmune ToleranceProtein BiosynthesisReceptors, Antigen, T-CellAnimalsAutoantigensMiceMice, Inbred C57BLSignal TransductionAutoantigensReceptors, Antigen, T-CellautoimmunitycancerCD8(+) T celldifferentiationdysfunctioneffector T cellexhaustionimmunotherapystem-like T celltolerance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.